Physician profile
Eric M Tate
NPI 1790869139
$2,200.85
in general payments reported to CMS, 2019-2025
19 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $110 · 2021: $351 · 2022: $153 · 2023: $206 · 2024: $574 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $880.23 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $483.03 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Coloplast Corp | $127.19 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $120.90 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Teleflex LLC | $120.58 | 2023 | Urolift |
| Merck Sharp & Dohme LLC | $108.04 | 2019-2025 | Verquvo |
| Pfizer INC. | $75.39 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.39 | 2023-2024 | Lifevest |
| Amarin Pharma, INC. | $48.86 | 2020 | |
| Abiomed | $31.80 | 2025 | |
| Lilly USA, LLC | $28.87 | 2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $27.07 | 2023 | Rexulti |
| Dexcom, INC. | $23.06 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $21.81 | 2024 | Voquezna |
| Abbvie INC. | $16.92 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $13.22 | 2023 | Gemtesa |
| Janssen Biotech, INC. | $8.49 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Tate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.